• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Schrodinger Inc. (Amendment)

    2/9/22 5:22:05 PM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SDGR alert in real time by email
    SC 13G/A 1 us80810d1037_020922.txt us80810d1037_020922.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) SCHRODINGER, INC. -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) 80810D103 -------------------------------------------------------- (CUSIP Number) January 31, 2022 -------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 80810D103 (1)Names of reporting persons. BlackRock, Inc. (2) Check the appropriate box if a member of a group (a) [ ] (b) [X] (3) SEC use only (4) Citizenship or place of organization Delaware Number of shares beneficially owned by each reporting person with: (5) Sole voting power 3002871 (6) Shared voting power 0 (7) Sole dispositive power 3057148 (8) Shared dispositive power 0 (9) Aggregate amount beneficially owned by each reporting person 3057148 (10) Check if the aggregate amount in Row (9) excludes certain shares (11) Percent of class represented by amount in Row 9 5.0% (12) Type of reporting person HC Item 1. Item 1(a) Name of issuer: ----------------------------------------------------------------------- SCHRODINGER, INC. Item 1(b) Address of issuer's principal executive offices: ----------------------------------------------------------------------- 1540 BROADWAY, 24TH FLOOR NEW YORK NY 10036 Item 2. 2(a) Name of person filing: ---------------------------------------------------------------------- BlackRock, Inc. 2(b) Address or principal business office or, if none, residence: ----------------------------------------------------------------------- BlackRock, Inc. 55 East 52nd Street New York, NY 10055 2(c) Citizenship: -------------------------------------------------------------------- See Item 4 of Cover Page 2(d) Title of class of securities: ------------------------------------------------------------------- Common Stock 2(e) CUSIP No.: See Cover Page Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a: [ ] Broker or dealer registered under Section 15 of the Act; [ ] Bank as defined in Section 3(a)(6) of the Act; [ ] Insurance company as defined in Section 3(a)(19) of the Act; [ ] Investment company registered under Section 8 of the Investment Company Act of 1940; [ ] An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E); [ ] An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F); [X] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G); [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940; [ ] A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J); [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: Item 4. Ownership Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. Amount beneficially owned: 3057148 Percent of class 5.0% Number of shares as to which such person has: Sole power to vote or to direct the vote 3002871 Shared power to vote or to direct the vote 0 Sole power to dispose or to direct the disposition of 3057148 Shared power to dispose or to direct the disposition of 0 Item 5. Ownership of 5 Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [ X ]. Item 6. Ownership of More than 5 Percent on Behalf of Another Person [ N/A ] Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. See Exhibit A Item 8. Identification and Classification of Members of the Group If a group has filed this schedule pursuant to Rule 13d-1(b)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identity of each member of the group. Item 9. Notice of Dissolution of Group Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5. Item 10. Certifications By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: February 9, 2022 BlackRock, Inc. Signature: Spencer Fleming ------------------------------------------- Name/Title Attorney-In-Fact The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature. Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001). Exhibit A Subsidiary Aperio Group, LLC BlackRock Advisors, LLC BlackRock (Netherlands) B.V. BlackRock Institutional Trust Company, National Association BlackRock Asset Management Ireland Limited BlackRock Financial Management, Inc. BlackRock Japan Co., Ltd. BlackRock Asset Management Schweiz AG BlackRock Investment Management, LLC BlackRock Investment Management (UK) Limited BlackRock Asset Management Canada Limited BlackRock Investment Management (Australia) Limited BlackRock Fund Advisors BlackRock Fund Managers Ltd *Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G. Exhibit B POWER OF ATTORNEY The undersigned, BLACKROCK, INC., a corporation duly organized under the laws of the State of Delaware, United States (the "Company"), does hereby make, constitute and appoint each of Christopher Meade, Daniel Waltcher, Una Neary, Richard Cundiff, Charles Park, Enda McMahon, Arlene Klein, Con Tzatzakis, Karen Clark, David Maryles, Daniel Ronnen, John Stelley, Daniel Riemer, Elizabeth Kogut, Maureen Gleeson, Daniel Kalish and Spencer Fleming acting severally, as its true and lawful attorneys-in-fact, for the purpose of, from time to time, executing in its name and on its behalf, whether the Company individually or as representative of others, any and all documents, is acting certificates, instruments, statements, other filings and amendments to the foregoing (collectively, "documents") determined by such person to be necessary or appropriate to comply with ownership or control-person reporting requirements imposed by any United States or non-United States governmental or regulatory authority, Including without limitation Forms 3, 4, 5, 13D, 13F, 13G and 13H and any amendments to any of the Foregoing as may be required to be filed with the Securities and Exchange Commission, and delivering, furnishing or filing any such documents with the appropriate governmental, regulatory authority or other person, and giving and granting to each such attorney-in-fact power and authority to act in the premises as fully and to all intents and purposes as the Company might or could do if personally present by one of its authorized signatories, hereby ratifying and confirming all that said attorney-in-fact shall lawfully do or cause to be done by virtue hereof. Any such determination by an attorney-in-fact named herein shall be conclusively evidenced by such person's execution, delivery, furnishing or filing of the applicable document. This power of attorney shall expressly revoke the power of attorney dated 8th day of December, 2015 in respect of the subject matter hereof, shall be valid from the date hereof and shall remain in full force and effect until either revoked in writing by the Company, or, in respect of any attorney-in-fact named herein, until such person ceases to be an employee of the Company or one of its affiliates. IN WITNESS WHEREOF, the undersigned has caused this power of attorney to be executed as of this 2nd day of January, 2019. BLACKROCK, INC. By:_ /s/ Daniel Waltcher Name: Daniel Waltcher Title: Deputy General Counsel
    Get the next $SDGR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SDGR

    DatePrice TargetRatingAnalyst
    7/2/2024$29.00Outperform
    Leerink Partners
    12/5/2023$38.00Overweight
    KeyBanc Capital Markets
    5/5/2023$60.00Overweight
    Piper Sandler
    12/19/2022$23.00Neutral
    Goldman
    3/1/2022$55.00Buy
    Citigroup
    11/19/2021$82.00 → $49.00Overweight → Equal-Weight
    Morgan Stanley
    11/19/2021$87.00Overweight
    Piper Sandler
    11/11/2021$80.00 → $52.00Buy → Neutral
    B of A Securities
    More analyst ratings

    $SDGR
    Financials

    Live finance-specific insights

    See more
    • Schrödinger Announces CFO Appointment

      Richie Jain to succeed Geoffrey Porges as CFO Schrödinger (NASDAQ:SDGR) today announced that the company and Geoffrey Porges, MBBS., have mutually agreed that Dr. Porges will depart from his role as chief financial officer to pursue other opportunities. Richie Jain, who previously served as Schrödinger's senior vice president, strategic finance and head of corporate and business development, will succeed Geoffrey Porges as chief financial officer. Dr. Porges will serve as an advisor to the company through June 6, 2025, to ensure a smooth transition. "I want to thank Geoff for his commitment and service during his tenure. He strengthened the company's financial profile to support continued

      5/20/25 6:30:00 AM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Schrödinger to Present Phase 1 Clinical Data on MALT1 Inhibitor SGR-1505 at EHA Annual Congress and International Conference on Malignant Lymphoma

      Company to host webcast to review data on Thursday, June 12, 2025 at 8:00 a.m. ET Schrödinger, Inc. (NASDAQ:SDGR) today announced that initial Phase 1 clinical data for SGR-1505, its investigational MALT1 inhibitor, will be presented at the European Hematology Association Annual Congress, taking place June 12 - 15, 2025, in Milan, Italy. Additional data from this trial will be presented at the International Conference on Malignant Lymphoma, taking place June 17 - 21, 2025, in Lugano, Switzerland. The Phase 1 study is designed to evaluate the safety, tolerability and anti-tumor activity of SGR-1505 in patients with relapsed/refractory B-cell malignancies. The poster presentations will incl

      5/14/25 9:30:00 AM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Schrödinger Reports Strong First Quarter 2025 Financial Results

      First Quarter Total Revenue of $59.6 Million, Software Revenue of $48.8 Million Initial SGR-1505 Phase 1 Clinical Data to be Presented in June Maintains 2025 Financial Guidance Schrödinger, Inc. (NASDAQ:SDGR) today announced financial results for the quarter ended March 31, 2025. "We are very pleased with Schrödinger's performance in the first quarter of 2025, with strong software and drug discovery revenue growth. Our proprietary pipeline is progressing, and we are looking forward to reporting initial data from the Phase 1 clinical study of SGR-1505 next month," said Ramy Farid, Ph.D., chief executive officer of Schrödinger. "More broadly, the pharmaceutical industry and even regulator

      5/7/25 4:05:00 PM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SDGR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Schrodinger Inc.

      SC 13G - Schrodinger, Inc. (0001490978) (Subject)

      11/13/24 4:30:25 PM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Schrodinger Inc. (Amendment)

      SC 13G/A - Schrodinger, Inc. (0001490978) (Subject)

      2/13/24 5:13:59 PM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Schrodinger Inc. (Amendment)

      SC 13G/A - Schrodinger, Inc. (0001490978) (Subject)

      1/23/24 11:52:31 AM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SDGR
    Leadership Updates

    Live Leadership Updates

    See more
    • Schrödinger Expands Executive Leadership Team with Appointment of Mannix Aklian as Chief Commercial Officer, Global Head of Software Sales and Marketing

      Schrödinger, Inc. (NASDAQ:SDGR) today announced the expansion of its leadership team with the appointment of Mannix Aklian as executive vice president, chief commercial officer, global head of software sales and marketing. Mr. Aklian brings more than 25 years of experience in software sales and leadership roles within the biopharmaceutical and technology industries. Mr. Aklian will have global oversight of Schrödinger's account management teams and will be responsible for the continued growth of the company's software business, including the go-to-market strategy for enhancements and new products within Schrödinger's computational platform. "Mannix joins Schrödinger at a pivotal time as w

      5/29/25 8:00:00 AM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Schrödinger Expands Board of Directors with Appointment of Bridget van Kralingen

      Schrödinger, Inc. (NASDAQ:SDGR) today announced the appointment of Bridget van Kralingen to its Board of Directors, effective March 7, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250310010062/en/Bridget van Kralingen was appointed to Schrödinger's Board of Directors in March 2025. (Photo: Business Wire) "Bridget has a proven track record of growing global software businesses, and we are pleased to welcome her to our Board," said Ramy Farid, Ph.D., chief executive officer of Schrödinger. "Bridget's leadership experience overseeing strategic initiatives at global technology companies, including IBM, will be valuable to Sch

      3/10/25 8:30:00 AM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Schrödinger Appoints Geoffrey Porges as Chief Financial Officer

      Schrödinger, Inc. (NASDAQ:SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced the appointment of Geoffrey Porges, MBBS., as chief financial officer. Dr. Porges brings to Schrödinger more than 30 years of experience in executive, advisory and investment roles within the biopharmaceutical industry. As Schrödinger's CFO, he will lead all aspects of the company's financial operations and investor relations and corporate affairs activities. He will also oversee business development and strategic planning for the company's proprietary pharmaceuticals and biopharmaceutical collaborations. This press release features multim

      8/18/22 7:01:00 AM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SDGR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $SDGR
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $SDGR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $SDGR
    SEC Filings

    See more
    • Officer Aklian Mannix Vartan was granted 14,063 shares (SEC Form 4)

      4 - Schrodinger, Inc. (0001490978) (Issuer)

      5/29/25 5:25:15 PM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Aklian Mannix Vartan

      3 - Schrodinger, Inc. (0001490978) (Issuer)

      5/29/25 5:24:05 PM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP & CFO Jain Rachit was granted 9,375 shares, increasing direct ownership by 34% to 37,097 units (SEC Form 4)

      4 - Schrodinger, Inc. (0001490978) (Issuer)

      5/22/25 4:23:22 PM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Commercial Officer

      Schrödinger, Inc. (NASDAQ:SDGR) today announced the grant of inducement equity awards to the company's newly appointed EVP, Chief Commercial Officer, Global Head of Software Sales & Marketing, Mannix Aklian. As previously announced, Mr. Aklian joined the company on May 28, 2025. The grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, as amended, were approved by the compensation committee of the board of directors pursuant to a delegation by the company's board of directors, effective as of May 29, 2025, and were made as a material inducement to Mr. Aklian's acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4) as a compone

      5/29/25 5:00:00 PM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Schrödinger Expands Executive Leadership Team with Appointment of Mannix Aklian as Chief Commercial Officer, Global Head of Software Sales and Marketing

      Schrödinger, Inc. (NASDAQ:SDGR) today announced the expansion of its leadership team with the appointment of Mannix Aklian as executive vice president, chief commercial officer, global head of software sales and marketing. Mr. Aklian brings more than 25 years of experience in software sales and leadership roles within the biopharmaceutical and technology industries. Mr. Aklian will have global oversight of Schrödinger's account management teams and will be responsible for the continued growth of the company's software business, including the go-to-market strategy for enhancements and new products within Schrödinger's computational platform. "Mannix joins Schrödinger at a pivotal time as w

      5/29/25 8:00:00 AM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

      Schrödinger, Inc. (NASDAQ:SDGR) today reported that on May 21, 2025, the company granted restricted stock units (RSUs) with respect to 7,051 shares of the company's common stock to seven newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company's board of directors, and were made as a material inducement to such employees' acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of his or her employment compensation. The RSUs vest over four years, with 25 percent of such RSUs vest

      5/23/25 8:30:00 AM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Leerink Partners initiated coverage on Schrodinger with a new price target

      Leerink Partners initiated coverage of Schrodinger with a rating of Outperform and set a new price target of $29.00

      7/2/24 8:03:41 AM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • KeyBanc Capital Markets initiated coverage on Schrodinger with a new price target

      KeyBanc Capital Markets initiated coverage of Schrodinger with a rating of Overweight and set a new price target of $38.00

      12/5/23 8:08:54 AM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler resumed coverage on Schrodinger with a new price target

      Piper Sandler resumed coverage of Schrodinger with a rating of Overweight and set a new price target of $60.00

      5/5/23 8:17:18 AM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Schrodinger Inc.

      8-K - Schrodinger, Inc. (0001490978) (Filer)

      5/20/25 6:44:43 AM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Schrodinger Inc.

      8-K - Schrodinger, Inc. (0001490978) (Filer)

      5/19/25 4:16:35 PM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 filed by Schrodinger Inc.

      S-8 - Schrodinger, Inc. (0001490978) (Filer)

      5/7/25 4:25:07 PM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care